Why the study?
ABP 710 is being developed as a biosimilar to infliximab and requires comparative phase 3 clinical trial data to demonstrate similarity in efficacy and safety.
Does ABP 710 provide similar efficacy and safety to the infliximab reference product in patients with moderate to severe rheumatoid arthritis?
RCT (n=558)
double-blind
randomized
Yes
Does ABP 710 provide similar efficacy and safety to the infliximab reference product in patients with moderate to severe rheumatoid arthritis?
Effect estimate: RD 9.3% (95% CI 2.67-15.96)
ABP 710 demonstrated similar efficacy and safety to the infliximab reference product in patients with moderate to severe rheumatoid arthritis, supporting its use as a biosimilar.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Honzík et al. (2010) conducted an RCT in moderate to severe rheumatoid arthritis (n=558). ABP 710 vs. infliximab reference product was evaluated on ACR20 at week 22 (RD 9.3%, 95% CI 2.67-15.96).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: